Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir.

Mustafa Ascha, Mona Ascha, N N Zein, N Alkhouri, B Eghtesad, K Abu-Elmagd, T Diago, I A Hanouneh

Abstract readCase Reports

In one paragraph

Article in International journal of organ transplantation medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.Canadian journal of gastroenterology & hepatology · 2016
Trial
Management of hepatitis c genotype 4 in the liver transplant setting.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mustafa AschaDepartment of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, United States.

Mona AschaDepartment of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, United States.

N N ZeinDepartment of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, United States.

N AlkhouriDepartment of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, United States.

B EghtesadDepartment of General Surgery, Transplant Center, Cleveland Clinic, Cleveland, Ohio, United States.

K Abu-ElmagdDepartment of General Surgery, Transplant Center, Cleveland Clinic, Cleveland, Ohio, United States.

T DiagoDepartment of General Surgery, Transplant Center, Cleveland Clinic, Cleveland, Ohio, United States.

I A HanounehDepartment of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) infection remains a leading indication for orthotopic liver transplantation (OLT) worldwide. Recurrence of HCV following OLT is universal. There is scarcity of data on the post-OLT treatment of HCV genotype-4-the predominant genotype in North Africa and the Middle East. Herein, we present three patients who have experienced HCV genotype-4 recurrence post-OLT. All three patients were interferon-naive and were treated with simeprivir (SIM) and sofosbuvir (SOF) combination therapy for 12-24 weeks. The data from this case series show that SIM+SOF are well-tolerated and effective for achieving viral clearance in HCV genotype-4 post-OLT patients. Given the limited nature of a case series, further research must be pursued regarding post-OLT HCV genotype-4 responses to direct-acting anti-viral therapy.

Indexed as

GenotypeHepacivirusInterferonLiver transplantation

Identifiers

PMID26082832

PMCPMC4464282

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.